Sera Prognostics, Inc., (SERA): Price and Financial Metrics

Sera Prognostics, Inc., (SERA): $9.46

0.04 (-0.42%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add SERA to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#62 of 65

in industry

SERA Price/Volume Stats

Current price $9.46 52-week high $10.44
Prev. close $9.50 52-week low $1.52
Day low $9.06 Volume 396,700
Day high $9.89 Avg. volume 238,718
50-day MA $8.33 Dividend yield N/A
200-day MA $4.29 Market Cap 296.45M

SERA Stock Price Chart Interactive Chart >

SERA Stock Summary

  • SERA's went public 2.47 years ago, making it older than just 5.71% of listed US stocks we're tracking.
  • For SERA, its debt to operating expenses ratio is greater than that reported by just 8.57% of US equities we're observing.
  • SERA's price/sales ratio is 522.28; that's higher than the P/S ratio of 99.05% of US stocks.
  • If you're looking for stocks that are quantitatively similar to SERA PROGNOSTICS INC, a group of peers worth examining would be CLPT, TARS, LAW, AXTI, and NSPR.
  • To check out SERA PROGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001534969.

SERA Valuation Summary

  • SERA's price/sales ratio is 567.9; this is 25713.64% higher than that of the median Healthcare stock.
  • SERA's EV/EBIT ratio has moved up 12.2 over the prior 30 months.

Below are key valuation metrics over time for SERA.

Stock Date P/S P/B P/E EV/EBIT
SERA 2023-12-29 567.9 2.5 -4.9 -4.7
SERA 2023-12-28 634.2 2.8 -5.5 -5.3
SERA 2023-12-27 601.2 2.6 -5.2 -5.0
SERA 2023-12-26 603.9 2.6 -5.2 -5.0
SERA 2023-12-22 625.8 2.7 -5.4 -5.2
SERA 2023-12-21 631.5 2.8 -5.5 -5.3

SERA Price Target

For more insight on analysts targets of SERA, see our SERA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.17 (Strong Buy)

Sera Prognostics, Inc., (SERA) Company Bio


Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.


SERA Latest News Stream


Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream


Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 11, 2023

While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail investors stood to gain the most

Key Insights Significant control over Sera Prognostics by retail investors implies that the general public has more...

Yahoo | December 7, 2023

Stocks Edge Higher On Hopes Of Soft Economic Landing

Easing labor costs, rising productivity, and a cooling labor market are supporting Wall Street this afternoon.

TalkMarkets.com | December 6, 2023

Why Is Sera Prognostics (SERA) Stock Up 260% Today?

With an oversight board recommending Sera Prognostics halt its clinical study for efficacy, SERA stock soared on the positive implications.

Josh Enomoto on InvestorPlace | December 6, 2023

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stoppi

Yahoo | December 6, 2023

Read More 'SERA' Stories Here

SERA Price Returns

1-mo 6.29%
3-mo 58.19%
6-mo 408.60%
1-year 148.95%
3-year N/A
5-year N/A
YTD 58.19%
2023 374.60%
2022 -81.66%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!